Fycompa (perampanel)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
Enquire now
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Fycompa (perampanel)

How to buy Fycompa: You can order Fycompa (perampanel) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Eisai Ltd
Disease Epilepsy
Indication Partial-onset seizures
Mode of Action AMPA receptor antagonist
Approval Status EMA approved (EU); FDA approved (USA); PMDA approved (JAP); TGA approved (AUS); HSA approved (SGP)
CAS Number 380917-97-5
HS Code 30043900
Strength 6 mg, 2 mg, 4 mg, 8 mg, 10 mg, 12 mg

Who is perampanel for?

Fycompa (perampanel) is used to treat adults and children from 12 years of age with partial-onset seizures (epileptic fits) with or without secondary generalisation [1].

Recommended dose

Complete information about Fycompa (perampanel) dosage and administration can be found here [2][3][4].
The standard dosage is:
  • at the start of treatment 2 mg per day,
  • if it is well tolerated it may be progressively increased by increments of 2 mg/day to a maximum dose of 12 mg per day [1].
Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered [2][3][4].
Consult your treating doctor for personalised dosing.

What is perampanel and how does it work?

Fycompa (perampanel) is an antiepileptic medicine used to treat adults and children from 12 years of age with partial-onset seizures (epileptic fits) with or without secondary generalisation [1].

Epilepsy is caused by excessive electrical activity in the brain. Although the precise mechanism by which Fycompa (perampanel) works is not fully understood, it is thought to block the action of the neurotransmitter glutamate. Neurotransmitters are naturally-occurring chemicals in the nervous system that allow nerve cells to communicate with each other. Glutamate is the main stimulatory neurotransmitter in nerve cells which can trigger and maintain seizures. Therefore by blocking glutamate’s actions, Fycompa (perampanel) is thought to stop epileptic seizures from occurring [1].

What is peramapanel's approval status?

Fycompa (perampanel) was approved by:
  • FDA (USA) October 22, 2012 [5]
  • EMA (EU) on July 07, 2012 [1]
  • TGA (AUS) on May 23, 2014 [4]
  • PMDA (JAP) on March 28, 2016 [6]
  • HSA (Singapore) on September 2014 [7]
for the treatment of partial-onset seizures in adults and children older than 12 years of age.

The approvals were based on several studies that have shown Fycompa (perampanel) to be more effective than placebo in reducing the frequency of epileptic seizures [1][3]. In one study, the percentage of patients who experienced a decrease in seizure frequency of at least 50% was 37.6 % for patients taking 8 mg Fycompa (perampanel) and 36.1 % for patients taking 12 mg Fycompa (perampanel), compared with 26.4 % of patients taking placebo. In another study, 33.3 % and 33.9 % of patients taking 8 mg and 12 mg Fycompa (perampanel) respectively showed a decrease in seizure frequency of at least 50 %, compared with 14.7 % of patients taking placebo. A third study showed a significant decrease in seizure frequency only in patients taking 4 mg and 8 mg Fycompa but not in patients taking a dose of 2 mg [1].
For patients with primary generalised tonic-clonic seizures, a type of generalized seizure that affects the entire brain, Fycompa (perampanel) was also more effective than placebo: 58 % of the patients given Fycompa (perampanel) had at least a 50 % reduction in frequency of seizures, compared with 36 % of those given the dummy treatment. Supportive evidence from patients treated for up to 2 years suggested that the benefit was maintained with longer treatment and that some patients could benefit from doses up to 12 mg [1].

The most common side effects are dizziness and somnolence (sleepiness).[1].

"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Share our website

Follow us

DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.